Acta otorrinolaringologica espanola · 2025
Diagnostic challenges of central compartment atopic disease in type-2 chronic rhinosinusitis.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moreno-Luna Ramón, Vizcarra Melgar Julissa, Martín Jiménez Daniel, Clari Comes Meritxell, Infante Cossio Pedro, Sánchez Gómez Serafín
Аннотация
BACKGROUND: Central compartment atopic disease (CCAD) is an emerging phenotype of type-2 chronic rhinosinusitis (CRS), characterized by inflammation involving the central nasal structures. The absence of standardized diagnostic criteria has hindered its recognition. This study aims to describe the first European cohort of CCAD patients and compare its features with previously published international data.
MATERIALS AND METHODS: A retrospective observational study was conducted including adult patients diagnosed with CCAD at a tertiary rhinology unit (2021-2024), based on predefined endoscopic and radiologic criteria. Demographic, clinical, exploratory, analytical and quality-of-life data were collected. Descriptive statistics were used to characterize the baseline profile of the study population.
RESULTS: The cohort of 93 CCAD patients was predominantly male (65.6%) with a mean age of 48.7 ± 12.2 years. The baseline SNOT-22 score averaged 61.5 ± 24.3, with marked olfactory impairment. Asthma and N-ERD were reported in 40.9% and 7.5% of cases, respectively; allergic sensitization was confirmed in 60.2%. The mean endoscopic scores were 4.0 ± 2.2 for the nasal polyp score and 7.5 ± 2.5 for the modified Lund-Kennedy scale, while the mean CT-scan score was 11.7 ± 3.8. Blood eosinophilia >150 cells/μL was present in 77.4% of patients, and tissue eosinophil counts averaged 49.9 ± 43.8 eosinophils per high-power field.
CONCLUSION: This study reinforces CCAD as a localized type-2 CRS phenotype with a distinctive atopic signature. Findings underscore the need for standardized diagnostic criteria to improve its recognition and guide more personalized therapeutic strategies.
MATERIALS AND METHODS: A retrospective observational study was conducted including adult patients diagnosed with CCAD at a tertiary rhinology unit (2021-2024), based on predefined endoscopic and radiologic criteria. Demographic, clinical, exploratory, analytical and quality-of-life data were collected. Descriptive statistics were used to characterize the baseline profile of the study population.
RESULTS: The cohort of 93 CCAD patients was predominantly male (65.6%) with a mean age of 48.7 ± 12.2 years. The baseline SNOT-22 score averaged 61.5 ± 24.3, with marked olfactory impairment. Asthma and N-ERD were reported in 40.9% and 7.5% of cases, respectively; allergic sensitization was confirmed in 60.2%. The mean endoscopic scores were 4.0 ± 2.2 for the nasal polyp score and 7.5 ± 2.5 for the modified Lund-Kennedy scale, while the mean CT-scan score was 11.7 ± 3.8. Blood eosinophilia >150 cells/μL was present in 77.4% of patients, and tissue eosinophil counts averaged 49.9 ± 43.8 eosinophils per high-power field.
CONCLUSION: This study reinforces CCAD as a localized type-2 CRS phenotype with a distinctive atopic signature. Findings underscore the need for standardized diagnostic criteria to improve its recognition and guide more personalized therapeutic strategies.